Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BM Pharma Consulting Pty Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, BURKETT, DANIEL JOHN. The prosecution is currently limited to 1 distinct art unit, reflecting a focused approach to its pending Biotechnology & Pharmaceuticals applications.
The busiest examiner, BURKETT, DANIEL JOHN, is responsible for 1 pending office action. As there is only 1 distinct examiner for the portfolio, this individual manages all currently pending matters. This concentration in 1 distinct art unit means that the company's immediate prosecution results depend on the review of a single examiner.
For a patent practitioner, the 1 pending office action represents the total active workload for the company. The involvement of 1 distinct examiner and 1 distinct art unit indicates a highly centralized prosecution environment. This structure allows for direct communication with BURKETT, DANIEL JOHN regarding the company's Biotechnology & Pharmaceuticals intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506847 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506847 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBM Pharma Consulting Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Daniel John Burkett has the most, with 1 of BM Pharma Consulting Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
